Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer

PURPOSE: Cetuximab demonstrates improved efficacy outcomes in patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS exon 2. Resistance to cetuximab is mediated by activating less frequent mutations in the RAS genes beyond KRAS exon 2. We performed extended RAS Mutational analysi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Res Treat
Hauptverfasser: Kim, Dalyong, Hong, Yong Sang, Kim, Jeong Eun, Kim, Kyu-pyo, Lee, Jae-Lyun, Chun, Sung-Min, Kim, Jihun, Jang, Se Jin, Kim, Tae Won
Format: Artigo
Sprache:Inglês
Veröffentlicht: Korean Cancer Association 2017
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5266405/
https://ncbi.nlm.nih.gov/pubmed/27121720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2016.069
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge